Key facts
- Stratus Therapeutics’s last known valuation is $210.0M (Jan 2023).
- It has raised $184.1M; the latest was Early Stage VC ($50.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, OrbiMed, Cormorant Asset Management, Monashee Investment Management, Ridgeback Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Stratus Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Stratus Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stratus Therapeutics
Operator of a biotech company intended to treat patients with blood, bone marrow, immune, and metabolic diseases. The company provides expertise in using zebrafish, mice, and human-induced pluripotent stem cells to clone and analyze novel genes and mechanisms important for blood formation, enabling patients to receive mechanism-based therapies.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 61
- Website
- stratustx.com/
- Ownership
- Privately Held (backing)
Stratus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stratus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stratus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.